Deeptech Breakthrough in Indian Biotech
Bengaluru-based Immuneel Therapeutics has successfully closed its Series B funding round, raising over Rs 100 crore ($10.5 million). The company, which specializes in cutting-edge cell and gene therapies, is leveraging this capital to solidify its position as a pioneer in India’s oncology treatment landscape.
Strategic Capital Allocation
The fresh injection of funds is earmarked for several mission-critical growth initiatives:
- Manufacturing Expansion: Scaling GMP-compliant manufacturing facilities to meet rising clinical demand.
- Commercialization: Accelerating the rollout of Qartemi, India’s first approved CAR-T therapy for Non-Hodgkin Lymphoma and leukemia.
- R&D Pipeline: Deepening research efforts into novel cell-based treatments.
- Geographic Expansion: Launching operations and clinical co-development partnerships across the Asia-Pacific region and the Middle East.
Market Context and Traction
Immuneel has maintained strong momentum since its inception in 2018. Following a previous Rs 100 crore extension in 2024, the company has now surpassed $50 million in total funding. The firm is backed by a prestigious roster of institutional investors and industry veterans, reflecting confidence in its ability to bridge the gap between complex biotechnology and scalable healthcare delivery.
Founder Perspective
Co-founded by Kiran Mazumdar-Shaw, Siddhartha Mukherjee, and Kush Parwar, Immuneel serves as a case study for founders in the capital-intensive deeptech sector. The company demonstrates that securing regulatory approvals for high-impact therapeutic products is the single most important catalyst for sustaining venture interest and market expansion.